PDCD1 and head and neck squamous cell carcinoma: Meanwhile, anti-PD-1 drugs nivolumab and pembrolizumab are Food and Drug Administration (FDA)-approved to treat recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).